CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $287 | -36.6% | 6,328 | -21.7% | 0.02% | -4.0% |
| Q2 2023 | $453 | +35.6% | 8,077 | -1.6% | 0.02% | +66.7% |
| Q1 2023 | $334 | 0.0% | 8,207 | 0.0% | 0.02% | 0.0% |
| Q4 2022 | $334 | -99.9% | 8,207 | -18.1% | 0.02% | -48.3% |
| Q3 2022 | $655,000 | +2.7% | 10,023 | -4.5% | 0.03% | +20.8% |
| Q2 2022 | $638,000 | +18.1% | 10,495 | +22.1% | 0.02% | +33.3% |
| Q1 2022 | $540,000 | +0.4% | 8,598 | +21.1% | 0.02% | +20.0% |
| Q4 2021 | $538,000 | -21.0% | 7,098 | +16.6% | 0.02% | -31.8% |
| Q3 2021 | $681,000 | -26.9% | 6,085 | +5.7% | 0.02% | -29.0% |
| Q2 2021 | $932,000 | +9.0% | 5,758 | -17.9% | 0.03% | -3.1% |
| Q1 2021 | $855,000 | -38.9% | 7,013 | -23.2% | 0.03% | -44.8% |
| Q4 2020 | $1,399,000 | +88.0% | 9,135 | +2.7% | 0.06% | +65.7% |
| Q3 2020 | $744,000 | +107.2% | 8,895 | +82.0% | 0.04% | +84.2% |
| Q2 2020 | $359,000 | – | 4,887 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |